metformin has been researched along with Amyloid Deposits in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a biguanide and the most commonly prescribed medication for type 2 diabetes Due to its pleiotropic properties, metformin's potential disease-modifying effects are widely studied on different pathophysiological plyers of AD such as amyloid-β (Aβ) production and clearance, tau phosphorylation, and neuroinflammation, in relevant in vitro and in vivo models." | 2.82 | Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings. ( Ghasemnejad-Berenji, M; Hodaei, D; Khezri, MR; Mahboubi, N; Yousefi, K, 2022) |
| "Metformin was administrated in the drinking water for 2 months." | 1.62 | Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. ( Chen, Y; Fan, Z; Li, K; Li, Z; Liu, Z; Shen, T; Tian, J; Yan, Y; Zhang, B; Zhao, S; Zhu, Y, 2021) |
| "Metformin is a biguanide antihyperglycemic drug used worldwide for the treatment of type 2 diabetes." | 1.62 | Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice. ( Araújo, SMR; Braga, CF; Duarte-Silva, E; França, MR; Lós, DB; Oliveira, WH; Peixoto, CA; Rocha, SWS; Rodrigues, GB, 2021) |
| "Metformin has been reported to have anti-inflammatory efficacy." | 1.48 | Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. ( Gong, Z; He, X; Huang, J; Kong, X; Li, J; Li, Q; Long, D; Ou, Z; Sun, X; Xu, B; Xu, L; Xuan, A; Zhang, L, 2018) |
| "Metformin treatment alone or with sitagliptin decreased islet amyloid deposition to a similar extent vs untreated mice." | 1.39 | One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. ( Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S, 2013) |
| "Diabetes increases the risk of Alzheimer's disease (AD)." | 1.38 | Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. ( Deng, J; Li, J; Sheng, W; Zuo, Z, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, QQ | 1 |
| Zhang, H | 1 |
| Guo, Z | 1 |
| Cai, ZL | 1 |
| Shen, ZH | 1 |
| Zhu, SJ | 1 |
| Tang, CL | 1 |
| Huang, SQ | 1 |
| Sheng, HJ | 1 |
| Sanati, M | 1 |
| Aminyavari, S | 1 |
| Afshari, AR | 1 |
| Sahebkar, A | 1 |
| Khezri, MR | 1 |
| Yousefi, K | 1 |
| Mahboubi, N | 1 |
| Hodaei, D | 1 |
| Ghasemnejad-Berenji, M | 1 |
| Chen, Y | 1 |
| Zhao, S | 1 |
| Fan, Z | 1 |
| Li, Z | 1 |
| Zhu, Y | 1 |
| Shen, T | 1 |
| Li, K | 1 |
| Yan, Y | 1 |
| Tian, J | 1 |
| Liu, Z | 1 |
| Zhang, B | 1 |
| Oliveira, WH | 1 |
| Braga, CF | 1 |
| Lós, DB | 1 |
| Araújo, SMR | 1 |
| França, MR | 1 |
| Duarte-Silva, E | 1 |
| Rodrigues, GB | 1 |
| Rocha, SWS | 1 |
| Peixoto, CA | 1 |
| Ou, Z | 1 |
| Kong, X | 1 |
| Sun, X | 1 |
| He, X | 1 |
| Zhang, L | 1 |
| Gong, Z | 1 |
| Huang, J | 1 |
| Xu, B | 1 |
| Long, D | 1 |
| Li, J | 2 |
| Li, Q | 1 |
| Xu, L | 1 |
| Xuan, A | 1 |
| Aston-Mourney, K | 1 |
| Subramanian, SL | 1 |
| Zraika, S | 1 |
| Samarasekera, T | 1 |
| Meier, DT | 1 |
| Goldstein, LC | 1 |
| Hull, RL | 1 |
| Deng, J | 1 |
| Sheng, W | 1 |
| Zuo, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Amyloid Deposits
| Article | Year |
|---|---|
Mechanistic insight into the role of metformin in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition; Disease Models, Animal; Hippoca | 2022 |
Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Diabetes Mellitus, Type 2; Humans; Hypogly | 2022 |
6 other studies available for metformin and Amyloid Deposits
| Article | Year |
|---|---|
[Comparative analysis of electroacupuncture, metformin and their combination on cognitive function and senile plaques of cerebral cortex and hippocampus in APP/PS1 mice].
Topics: Animals; Cerebral Cortex; Cognition; Electroacupuncture; Hippocampus; Male; Metformin; Mice; Plaque, | 2021 |
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Disease Models, A | 2021 |
Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitu | 2021 |
Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Hippocampus; Male | 2018 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; H | 2013 |
Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Conditioning, Psychological; Diabetes Mellitus, T | 2012 |